Miracell Selected as National Representative for Health and Diagnostic Innovation
Independently Developed Stem Cell Extractor
Successfully Localized US-Production Alternative
Opening New Paths to Treating Incurable Diseases
Stem cell specialist Miracell has been selected as a “National Representative Innovative Company” by the government. Miracell announced on the 8th that it was selected as a National Representative Innovative Company by the Financial Services Commission, based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare.
The National Representative Innovative Company is a system in which nine ministries, including the Ministry of Trade, Industry and Energy, the Ministry of SMEs and Startups, the Ministry of Science and ICT, the Ministry of Health and Welfare, and the Ministry of Oceans and Fisheries, select representative innovative companies from each industry and provide various support programs to foster them as future core companies. This corporate support system was decided on at the 12th meeting of the Central Economic Response Headquarters on July 30, 2020.
Miracell was selected as one of the “Health and Diagnostic Innovative Companies” in the fields of new health technologies, medical devices, and innovative pharmaceuticals, based on selection criteria established by the Ministry of Health and Welfare.
Miracell is a stem cell company launched in 2009, adopting Harvard University’s cell extraction technology.
In 2017, it successfully developed a “minimally manipulated stem cell isolation and amplification source technology.” The Ministry of SMEs and Startups selected this technology as a small and medium-sized enterprise (SME) commercialization technology development project.
Based on this technology, Miracell successfully developed and domestically produced the SMART M-CELL2 kit, a replacement for the SmartPReP2 kit developed by the Harvard Medical School Immunology Research Institute in 2018 and exported globally. Tests at Seoul National University Bundang Hospital showed that its performance was comparable to or even superior to that of the SmartPReP2 kit. The SMART M-CELL2 extracts large quantities of stem cells by concentrating bone marrow blood extracted from the body through centrifugation. It is currently used in major hospitals both domestically and internationally.
Miracell CEO Shin Hyun-soon stated, “Being selected as a National Representative Innovative Company is very significant. It opens up a new avenue for scientifically treating rare and intractable diseases, as well as Parkinson’s disease and intractable chronic renal failure, using stem cells.” Shin explained, “Stem cell therapy involves extracting bone marrow blood from the patient’s own body, concentrating it through centrifugation, extracting a large number of stem cells, and then reinjecting them into the body.”
“Because old cells are regenerated into healthy ones, the effect of improving the body’s functions is remarkable.”
Smart Mcell 2, recognized as an innovative technology, is a biopharmaceutical manufacturing technology. It is a cutting-edge system for “bone marrow and blood stem cell manufacturing,” extracting hematopoietic stem cells (CD34+) from blood and mesenchymal stem cells from bone marrow. Approximately 2.9 billion cells can be separated and extracted in one session, and the cell survival rate is as high as 80-98%. It features an automated system that prevents cell mutation.
The Smart Mcell 2 is equipped with a special light-emitting diode (LED) to enhance cell activity, transitioning from the existing analog method to a digital one.
It is also equipped with voice support, earning it recognition as a cutting-edge bio-healthcare medical device.
Miracell, which began its medical business in 1986, has been dedicated to research and development as a stem cell specialist since 2007.
In particular, its biological drug manufacturing technology has been certified by the Ministry of Health and Welfare as a new medical technology that helps treat conditions such as acute myocardial infarction, critical limb ischemia, and cartilage defects.
Furthermore, it has secured various core technologies, including GMP, ISO13485, ISO9001, and CE European Union certifications, and 22 patent applications for cell extraction technology.
Lee Jin-han, Medical Reporter